Scarica l'app Stockscreener
24.49
3.05%
-0.77
Dopo l'orario di chiusura:
24.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$25.26
Aprire:
$25.36
Volume 24 ore:
814.26K
Relative Volume:
0.85
Capitalizzazione di mercato:
$1.62B
Reddito:
$9.98M
Utile/perdita netta:
$-154.08M
Rapporto P/E:
-9.4922
EPS:
-2.58
Flusso di cassa netto:
$-159.66M
1 W Prestazione:
+1.96%
1M Prestazione:
-3.09%
6M Prestazione:
-35.74%
1 anno Prestazione:
-30.47%
Intervallo 1D:
$24.24
$25.89
Intervallo di 1 settimana:
$23.83
$26.26
Portata 52W:
$22.16
$53.18
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Confronta CLDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
24.49 | 1.62B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-07 | Iniziato | Citigroup | Buy |
| 2024-09-30 | Iniziato | Goldman | Neutral |
| 2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2023-12-20 | Iniziato | TD Cowen | Outperform |
| 2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Iniziato | Wells Fargo | Underweight |
| 2021-09-17 | Iniziato | Jefferies | Buy |
| 2021-09-10 | Iniziato | SVB Leerink | Outperform |
| 2021-07-22 | Iniziato | Guggenheim | Buy |
| 2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-07 | Iniziato | Aegis Capital | Buy |
| 2016-03-08 | Downgrade | Jefferies | Buy → Hold |
| 2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-01 | Iniziato | H.C. Wainwright | Buy |
| 2015-08-11 | Reiterato | Brean Capital | Buy |
| 2015-08-11 | Reiterato | Oppenheimer | Outperform |
| 2015-08-11 | Reiterato | ROTH Capital | Buy |
| 2015-06-02 | Reiterato | WBB Securities | Strong Buy |
| 2014-11-17 | Reiterato | ROTH Capital | Buy |
| 2014-03-04 | Reiterato | Oppenheimer | Outperform |
| 2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-02-26 | Reiterato | Oppenheimer | Outperform |
| 2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2012-10-02 | Reiterato | Oppenheimer | Outperform |
| 2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Celldex Therapeutics' (CLDX) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by SG Americas Securities LLC - Defense World
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock outlook - Investing.com India
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - MSN
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews - Benzinga
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Cantor Fitzgerald Forecasts CLDX FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts CLDX FY2025 Earnings - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expands By 10.7% - MarketBeat
Analysts Provide Insight Into Celldex Therapeutics Inc’s (CLDX) Potential. - Stocks Register
B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR
Celldex stock hits 52-week low at $22.89 amid market challenges By Investing.com - Investing.com South Africa
Celldex stock hits 52-week low at $22.89 amid market challenges - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowHere's What Happened - MarketBeat
Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada
Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights
Guggenheim maintains $90 target on Celldex stock after study By Investing.com - Investing.com Canada
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap UpHere's Why - MarketBeat
Before You Invest, Make Sure You Check This Asset Entities Inc (NASDAQ: ASST) Analysis - Stocks Register
What Do Wall Street Analysts Think About Celldex Therapeutics Inc (NASDAQ: CLDX) Stock? - Stocks Register
Why Is Jasper Therapeutics Stock Trading Lower On Wednesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Celldex Therapeutics' SWOT analysis: barzolvolimab potential drives stock outlook By Investing.com - Investing.com Canada
Celldex Therapeutics’ SWOT analysis: barzolvolimab potential drives stock outlook By Investing.com - Investing.com Nigeria
Celldex Therapeutics' SWOT analysis: barzolvolimab potential drives stock outlook - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in urticaria By Investing.com - Investing.com Nigeria
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria By Investing.com - Investing.com South Africa
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Drops By 5.1% - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Barclays PLC Has $4.43 Million Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
What Analysts Are Saying About Celldex Therapeutics Stock - Benzinga
Celldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis - The Manila Times
Celldex Launches Pivotal Phase 2 Trial for Novel Atopic Dermatitis Treatment, Targeting 20% of US Population - StockTitan
State Street Corp Sells 173,932 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential By Investing.com - Investing.com Nigeria
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 5.5%Here's Why - MarketBeat
BNP Paribas Financial Markets Boosts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
XTX Topco Ltd Makes New $1.56 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):